Competitive: CK Group: CK Clinical are recruiting for a Director, Head of Translational Biomarker Discovery to join an innovative and successful biotech company who have products on the... Cambridge

Funding Opportunity RFA-DK-22-513 from the NIH Guide for Grants and Contracts. This is a non-competitive funding opportunity intended to fund a single award. The NIDDK is announcing its intent to issue a single source cooperative agreement award to the University of Michigan. The purpose of this Single SourceLimited Competition is to extend the Cure Glomerulonephropathy (CureGN) Network by continuing to support the Data Coordinating Center (DCC). The CureGN Network is a multicenter observational cohort study of glomerular disease patients with the goal of improving care for all glomerular disease patients. The DCC provides key leadership functions for this study in the areas of study organization, study design and implementation, overall management, data management and analysis, and biosample management. The CureGN Participating Clinical Centers (PCCs) will continue to follow-up previously enrolled participants under a separate NOFO.

Funding Opportunity RFA-EB-23-007 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the NeuroImaging Tools and Resources Collaboratory and to enable collaborative research in neuroimaging informatics. The competition is limited to the U24 awardees and subawardees of RFA-EB-16-002.

Funding Opportunity RFA-AT-24-005 from the NIH Guide for Grants and Contracts. This initiative will support a research resource for the continuation of a database of controlled trials of complementary and integrative health interventions, which are useful to those conducting systematic reviews. The research team will need to describe how to establish a database, maintain an existing database, or convert an existing database, as well as how it will be maintained and kept current during the award. The initiative will encourage increasing outreach, access, and availability of the database to a broader scientific community, the public and policy makers. The resource should update multiple reviews with current evidence and conduct new systematic reviews each year focusing on topics that are of priority to NCCIH (NCCIH Strategic Plan 2021-2025), particularly topics related to whole person research that include multi-component complementary and integrative health interventions. In the context of whole person health, topics should focus on the exploration of the fundamental science of interconnected systems, investigating multicomponent interventions or therapeutic systems, and/or examining the impact of these interventions on multisystem or multiorgan outcomes are of particular interest.

Notice NOT-NR-23-013 from the NIH Guide for Grants and Contracts

Notice NOT-GM-23-047 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-24-151 from the NIH Guide for Grants and Contracts. The goal of CTDPACC is to support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial. The Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC) will provide executive management, direction, and overall coordination, including data processing and analysis to support the Clinical High Risk (CHR) for Psychosis Clinical Trial Network companion FOA. That Network validates the utility of drug development tools (biomarkers, algorithms, clinical outcome measures) previously assessed in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) project. The CTDPACC will support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial utilizing a Phase 2 ready compound or compounds.

Funding Opportunity RFA-MH-24-150 from the NIH Guide for Grants and Contracts. To use a subset of drug development tools, which are being assessed in the AMP SCZ observational study, in a PoP trial with CHR individuals to determine the ability to detect a biological and/or clinical signal with the compound or compounds selected to use within a 12-16 week study period. The PoP trial will assess the performance of the PSYCHS, other clinical outcome measures, and biological measures. The compound or compounds that are selected for testing in the CHR Clinical Trial Network will affect a pathophysiologically relevant mechanism and have the potential to produce a detectable signal on biological and clinical outcome measures within a 12-16 week period of study.

Notice NOT-NS-23-092 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-151 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-23-233 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see PHS 2023-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funding Opportunity PA-23-232 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

Funding Opportunity PA-23-230 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

Funding Opportunity PA-23-231 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH and CDC awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funding Opportunity PAR-23-220 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The NOFO aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. This Notice of Funding Opportunity requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funding Opportunity PAR-23-219 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The NOFO aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. Clinical Trials are not accepted under this NOFO.

We’re supporting exciting new initiatives to enable bioinformatics analysis pipelines, spatial transcriptomics and precision oncology. $123,203 - $194,739 a year
From Fred Hutchinson Cancer Research Center - Wed, 12 Jul 2023 00:40:48 GMT - View all Seattle, WA jobs

John Wiley & Sons , Inc.: The Bioinformatics Engineer will have the opportunity to support cutting edge clinical oncology diagnostic pipelines supporting high quality patien... Oklahoma City, Oklahoma

Notice NOT-MH-23-335 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-336 from the NIH Guide for Grants and Contracts